Johnson & Johnson stays out of obesity race due to strong competition
US pharmaceutical company Johnson & Johnson has no plans to invest in the development of drugs for obesity treatment, as the competition is already too great, said J&J CEO Joaquin Duato on Tuesday at an investor conference, Bloomberg News reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
J&J psoriasis drug sales falter as competition heats up
For subscribers